Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zipalertinib - Cullinan Therapeutics

Next Previous
Drug Profile

Zipalertinib - Cullinan Therapeutics

Alternative Names: CLN-081; TAS-6417; TPC-064

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Cullinan Therapeutics; Taiho Pharmaceutical
  • Class Acrylamides; Amines; Antineoplastics; Indolizines; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer

Most Recent Events

  • 20 Nov 2025 Preregistration for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 20 Nov 2025 Taiho Pharmaceutical and Cullinan Therapeutics plans to complete the rolling NDA submission for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) to US FDA, in the first quarter of 2026
  • 20 Nov 2025 Taiho Pharmaceutical and Cullinan Therapeutics plans to request priority review for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) to US FDA, in the first quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top